Opioids Market, By Product Type (Immediate Release Opioid, Extended Release Opioid), By Application (Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and De-Addiction) – U.S Insights, Trends and Forecast, 2017-2025

Created On: Jun-2018
Report ID: IR59
Format: PDF

Opioids Market: Introduction

An opioid refers to type of narcotic pain medication used to treat severe or moderate pain. It is used as a cough suppressant, anesthesia, and diarrhea suppressant in order to reduce surgical pain, cancer pain, injury and pain arising from any disease. Opioids are mainly used in pain management associated with cancer and end-stage diseases in which proper care is required.

Market Dynamics

The opioids market size in U.S is expected to rise over the forecast period, due to escalation in chronic pain, arthritis, cancer incidences, coupled with favorable reimbursement policies and growing utilization of opioids in non-cancer conditions and for palliative care. Beside the use of analgesic they are extensively used in production of cough suppressants and antidiarrheal medicines.

As per a U.S. Census Bureau report which is titled as “An Aging World 2015”, out of global population of 7.3 billion, around 8.5% population was estimated to be the age of 65 or above. Rising geriatric population is increasing the prevalence of diseases such as and cancer and rheumatoid arthritis thus resulting to the growth of the opioids market share. In addition to this rise in palliative and services health care centers are resulting to the increase in the demand for opioids in recent years.

However stringent government regulations possess a major threat to the U.S opioids market size. For instance, US FDA stringently regulates the opioids market, due to rising mortality rates from drug abuse. Additionally, FDA release guideline for the manufacture, marketing and distribution of opioids. FDA also recommends to use NSAIDS over the opioids for the treatment of the pain. Moreover, extended consumption of opioids results in addiction of the drug, and increased death rates. As per, American Society of Addiction Medicine approximately 18,893 people died from the overdose of drugs.

 

Segment Analysis:

The extended release opioid segment is projected to be holding the major revenue share over the forecast period, owing to their increase relevance in pain management, coupled with development of transdermal patches. According to National Center for Biotechnology Information (NCBI), extended release prescribed opioids are better for patients than immediate release opioids because extended release formulations are especially designed to allow a controlled release of the active agent. The controlled release of active agents provides prolonged and relatively consistent plasma drug levels with lower maximum concentration and fewer peak-to-trough fluctuations.

Among the application segment, use of opioid for treatment of pain is anticipated to generate the major revenue share over the forecast period, due to its powerful analgesic properties, and escalation in clinical studies on the utilization of opioid in combinations to develop safe medicines. Anesthesia Opioids are projected to grow rapidly over the forecast period, owing to their potential in achieving cardiovascular activities and increased clinical studies on utilization of opioid in developing safe anesthetics.

Competitive Landscape:

The opioids market is highly regulated and consists of some prominent players who focus upon continuous product innovation. Key market players in the opioids market include Sun Pharmaceutical Industries, Sanofi S.A, Janssen Pharmaceutical Inc., Pfizer Inc., Endo International Plc, Egalet Corporation, Titan Pharmaceuticals and Purdue Pharma among others. Key players are concentrating on the development of novel drugs and their approval from regulatory authorities in order to launch them commercially for treating problems like chronic pain and others. For instance – In June 2018, an American biopharmaceutical company announced the submission of a new drug application to the FDA for NKTR-181, an analgesic opioid molecule. The submitted drug application is proposed to be used in treating chronic lower back pain.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us